Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.
Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.
复制标题
前列腺癌和骨代谢标志物：诊断、预后和治疗意义。
DOI：
10.1007/s00345-007-0186-3
复制
发表时间：
2007
影响因子：
3.4
通讯作者：
LaraJr,PrimoN
中科院分区：
文献类型：
--
作者：
Nelson,EricC;Evans,ChristopherP;Pan,Chong-Xian;LaraJr,PrimoN
骨转移并发晚期前列腺癌（CaP）的知识越来越相关的新疗法的患者选择。目前核骨显像对前列腺转移瘤的特异性有限。由于血清骨标志物确实与骨病变相关，因此它们在晚期CaP患者中可能发挥多种作用。目前，这些标志物在CaP的预后列线图中发挥作用。最近的研究表明，骨标志物在诊断和选择患者进行新疗法中的作用不断扩大。在未来，这些标志物通路中的一些的治疗作用将出现，最终允许患者护理的更大的个性化。
Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.